Results 71 to 80 of about 13,664 (205)

Clinical Outcomes of a Pharmacy-Led Blood Factor Stewardship Program [PDF]

open access: yes, 2015
To report the results of a pharmacist-directed blood factor stewardship program targeting off-label utilization designed to limit use to established organizational guidelines in high-risk populations. Prospective evaluation of recombinant factor VIIa and
Kiel, Patrick J.   +2 more
core   +1 more source

cGAS Inhibits ALDH2 to Suppress Lipid Droplet Function and Regulate MASLD Progression

open access: yesAdvanced Science, Volume 12, Issue 46, December 11, 2025.
cGAS is a cytosolic DNA sensor known for innate immune defense. cGAS binds and suppresses ALDH2 are showed, limiting acetyl‐CoA production. cGAS loss activates ALDH2, promoting histone acetylation, lipogenesis, and lipid droplets accumulation. cGas‐/‐ mice on a high‐fat diet show signs of worsened MASLD.
Ying Wang   +14 more
wiley   +1 more source

Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients

open access: yesDrug Design, Development and Therapy, 2010
John PuetzSaint Louis University, Department of Pediatrics, St Louis, Missouri, USAAbstract: One of the last remaining clinical hurdles in the treatment of people with hemophilia is the development of inhibitors. Alloantibodies or autoantibodies directed
John Puetz
doaj  

Sequential therapy: an option for hemophiliac patients not responding to monotherapy with bypassing agents. Observational study of the GrHeCol (Grupo Hemofilia Colombia)

open access: yesIatreia, 2018
Introduction and objectives: Patients diagnosed with severe hemophilia are at risk of developing inhibitors of low or high title, being the treatment of choice for this latter group of patients the immune tolerance therapy (ITI).
Casas, Claudia Patricia   +5 more
doaj   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors

open access: yesBritish Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander   +206 more
wiley   +1 more source

Management of neonatal massive hemorrhage: A narrative review

open access: yes
Transfusion, EarlyView.
Cheryl S. L. Chooi   +7 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

open access: yesBritish Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander   +31 more
wiley   +1 more source

Successful Hemostasis with Recombinant Activated Factor VII in a Patient with Massive Hepatic Subcapsular Hematoma

open access: yesCase Reports in Gastroenterology, 2009
Recombinant activated coagulation factor VII (rFVIIa) is known to be effective in the management of acquired deficiencies of factor VII and platelet function defects.
Ju-Hee Lee   +12 more
doaj   +1 more source

Okanin Suppresses the Growth of Colorectal Cancer Cells by Targeting at Peroxiredoxin 5

open access: yesAdvanced Science, Volume 12, Issue 43, November 20, 2025.
Okanin suppresses colorectal cancer growth by directly targeting PRDX5. This natural compound selectively binds peroxiredoxin 5 (PRDX5), inhibiting its activity and inducing WSB1‐mediated degradation. PRDX5 loss elevates ROS, suppresses GPX4 via SIAH2, and further triggers cell death (apoptosis and ferroptosis).
Ji Zhong Zhao   +9 more
wiley   +1 more source

Overview of the use of recombinant factor VIIa in children

open access: yesPediatric Health, Medicine and Therapeutics, 2014
John Puetz Department of Pediatrics, Division of Hematology/Oncology, Cardinal Glennon Children's Medical Center, Saint Louis University, St Louis, MO, USA Abstract: Recombinant factor VIIa (rFVIIa) was initially developed as a bypassing agent to ...
Puetz J
doaj  

Home - About - Disclaimer - Privacy